12.04.2012

Lonza, Agennix Sign Deal for Production of Talactoferrin

Lonza and Agennix announced an agreement for the production of Agennix's first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC). more03.04.2012

Lonza Appoints Richard Ridinger as New CEO

At a meeting on 2 April 2012, the Board of Directors of Lonza elected Richard Ridinger as the new CEO of Lonza. Mr. Ridinger, 53, will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January. more26.01.2012

Stefan Borgas Fired as Lonza CEO

Drugs industry supplier Lonza Group ditched Chief Executive Stefan Borgas after profit last year plunged by a third and warned 2012 would pose further challenges because of a strong franc and problems at pharmaceutical firms. more08.12.2011

M&A in the Chemical Industry

Megadeals - What trends are influencing deals in the chemical industry? There are several, according to the latest edition of PricewaterhouseCooper's (PwC)Chemical Compounds report, which analyzes M&A activity in the global chemical industry. The report finds that while the number of M&As dropped during Q3 2011, the proportion of megadeals (deals valued at $1 billion or more) increased.
more31.10.2011

Lonza Sees Growth on Pharma Outsourcing

Swiss drugs industry supplier Lonza is set to grow underlying sales and operating profit this year despite the strong Swiss franc as it benefits from robust demand from pharmaceutical groups, particularly at a plant in China. more28.10.2011

Peter Pollak on the World of Fine Chemicals

In his book "Fine Chemicals - The Industry and the Business," Dr. Peter Pollak provides a comprehensive view on one of the most challenging segments of the modern chemical industry, and a practical guide for succeeding in the multibillion dollar fine chemicals business.
more26.10.2011

Pharma’s Future with a Disaggregated Supply Chain

New Rules -The game has changed for the global pharmaceutical industry. Numerous forces are shaping this new pharmaceutical era: The rise of emerging markets, increasing price pressure and expiring patents are just some of the factors forcing pharmaceutical companies to change the way they operate and how they manage their value chain.
more24.10.2011

Pharma Must Make Big Changes to Survive

Patent cliff, the rise of "pharmerging" markets: These are just a few of the challenges the global pharmaceutical industry is facing. In order to ward off billions of dollars in losses, pharma companies will have to redesign their supply chains and become less squeamish about outsourcing more and more elements of their businesses.
more29.09.2011

Lonza Obtains French Antitrust Clearance For Arch Chemicals Offer

Lonza Group, a supplier to the life science industries, said it has obtained antitrust clearance from the Autorité de la Concurrence in France for its tender offer for 100% of the outstanding shares of common stock of Arch Chemicals. more10.08.2011

Lonza To Build Formulation Plant in Visp

Lonza said it will be investing CHF 5.8 million in a formulation plant for its Meta metaldehyde in Visp, Switzerland. The company said the plant will enable it to supply its own formulations, allowing Lonza to serve the market with metaldehyde as an active substance, as well as with ready-made slug pellets. The plant is expected to come online in the second half of 2012.   more